These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30758590)

  • 1. [Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
    Schröder W; Bruns CJ
    Chirurg; 2019 Mar; 90(Suppl 2):27. PubMed ID: 30758590
    [No Abstract]   [Full Text] [Related]  

  • 2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
    Al-Batran SE; Goetze TO; Mueller DW; Vogel A; Winkler M; Lorenzen S; Novotny A; Pauligk C; Homann N; Jungbluth T; Reissfelder C; Caca K; Retter S; Horndasch E; Gumpp J; Bolling C; Fuchs KH; Blau W; Padberg W; Pohl M; Wunsch A; Michl P; Mannes F; Schwarzbach M; Schmalenberg H; Hohaus M; Scholz C; Benckert C; Knorrenschild JR; Kanngießer V; Zander T; Alakus H; Hofheinz RD; Roedel C; Shah MA; Sasako M; Lorenz D; Izbicki J; Bechstein WO; Lang H; Moenig SP
    BMC Cancer; 2017 Dec; 17(1):893. PubMed ID: 29282088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options.
    Liakakos T; Katsios C; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):1-4. PubMed ID: 21309665
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
    Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
    Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. It is time for a proper staging system for adenocarcinoma of the gastroesophageal junction.
    Pedrazzani C; de Manzoni G; Marrelli D; Roviello F
    J Clin Oncol; 2007 Mar; 25(7):907-8; author reply 908-9. PubMed ID: 17327616
    [No Abstract]   [Full Text] [Related]  

  • 8. [Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].
    Ben Salah H; Bahri M; Dhouib F; Daoud J
    Cancer Radiother; 2016 Dec; 20(8):830-832. PubMed ID: 27793531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term survival after perioperative chemotherapy of cancer of the gastroesophageal junction and the stomach-ECF vs. FLOT].
    Schröder W; Bruns CJ
    Chirurg; 2020 Feb; 91(2):166. PubMed ID: 31993693
    [No Abstract]   [Full Text] [Related]  

  • 10. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for Esophageal Adenocarcinoma.
    Lam KO; Kwong DLW
    Methods Mol Biol; 2018; 1756():19-34. PubMed ID: 29600357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
    Schröder W; Bruns CJ
    Chirurg; 2017 Jun; 88(6):540. PubMed ID: 28477062
    [No Abstract]   [Full Text] [Related]  

  • 13. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
    Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
    Lutz MP; Zalcberg JR; Ducreux M; Adenis A; Allum W; Aust D; Carneiro F; Grabsch HI; Laurent-Puig P; Lordick F; Möhler M; Mönig S; Obermannova R; Piessen G; Riddell A; Röcken C; Roviello F; Schneider PM; Seewald S; Smyth E; van Cutsem E; Verheij M; Wagner AD; Otto F
    Eur J Cancer; 2019 May; 112():1-8. PubMed ID: 30878666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FLOT becomes standard neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction and stomach].
    Treese C; Harloff H; Daum S
    Z Gastroenterol; 2017 Sep; 55(9):881-882. PubMed ID: 29186642
    [No Abstract]   [Full Text] [Related]  

  • 16. Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions.
    Saba NF
    Oncology (Williston Park); 2014 Jun; 28(6):520-1. PubMed ID: 25134327
    [No Abstract]   [Full Text] [Related]  

  • 17. Curative management of adenocarcinoma of the oesophagus and oesogastric junction--current recommendations of the Belgian Working Group.
    Van Laethem JL; Baert F; Buset M; de Hemptine B; De Ronde T; Honoré P; Lerut T; Scaillet P; Van Cutsem E;
    Acta Gastroenterol Belg; 2000; 63(3):304-6. PubMed ID: 11189997
    [No Abstract]   [Full Text] [Related]  

  • 18. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
    Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
    Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CLINICAL RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH ESOPHAGEAL AND ESOPHAGOGASTRIC JUNCTION CANCERS].
    Bišof V; Juretić A; Stančić-Rokotov D; Rustemović N; Miletić D; Boban M; Omrčen T; Razumović JJ; Pavlović I; Fröbe A; Čonkaš M; Rakušić Z; Gugić D
    Lijec Vjesn; 2016; 138(9-10):233-9. PubMed ID: 30148543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma.
    Tepper JE; O'Neil B
    J Clin Oncol; 2009 Feb; 27(6):836-7. PubMed ID: 19139425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.